| Alatrash G, Albitar M, O'Brien S, et al.
Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). [JOURNAL ARTICLE]
Br J Haematol 2009 Nov 6.
Abstract | Full Citation | Find Related Articles |
| Führer M, Claviez A, Klein B, et al.
Re-Transplantation from the Same Unrelated Donor in Three Adolescents with Severe Aplastic Anemia After Graft Rejection. [JOURNAL ARTICLE]
Klin Padiatr 2009 Nov; 221(6):358-361.
Abstract | Full Citation |
| Narimatsu H, Oiso G, Ono S, et al.
Critical Review of the Determination Process by the Japanese Reviewing Authority in Approving the Additional Efficacy of Fludarabine Phosphate. [JOURNAL ARTICLE]
J Clin Oncol 2009 Nov 2.
Full Citation | Publisher Full Text | Find Related Articles |
| Schlette EJ, Schlette EJ, Admirand J, et al.
p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy. [Journal Article]
Leuk Lymphoma 2009 Oct; 50(10):1597-605.
Abstract | Full Citation |
| Byrd JC, Byrd JC, Peterson BL, et al.
Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. [Journal Article]
Leuk Lymphoma 2009 Oct; 50(10):1589-96.
Abstract | Full Citation |
| Yin W, Karyagina EV, Lundberg AS, et al.
Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate. [JOURNAL ARTICLE]
Biopharm Drug Dispos 2009 Oct 26.
Abstract | Full Citation |
| Morrison VA
Infectious Complications in Patients With Chronic Lymphocytic Leukemia: Pathogenesis, Spectrum of Infection, and Approaches to Prophylaxis. [JOURNAL ARTICLE]
Clin Lymphoma Myeloma 2009 Oct 1; 9(5):365-370.
Abstract | Full Citation |
| Malcikova J, Smardova J, Rocnova L, et al.
Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival and response to DNA damage. [JOURNAL ARTICLE]
Blood 2009 Oct 22.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |
| Byrd JC, Kipps TJ, Flinn IW, et al.
Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. [JOURNAL ARTICLE]
Blood 2009 Oct 20.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |
| Smolej L
Modern concepts in the treatment of chronic lymphocytic leukemia. [Journal Article]
Hematology 2009 Oct; 14(5):249-54.
Abstract | Full Citation | Find Related Articles |
   |
